Hobart Private Capital LLC Has $2.10 Million Stock Position in Eli Lilly and Company $LLY

Hobart Private Capital LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 26.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,753 shares of the company’s stock after purchasing an additional 573 shares during the period. Hobart Private Capital LLC’s holdings in Eli Lilly and Company were worth $2,101,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of LLY. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the second quarter valued at about $29,000. Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc raised its stake in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 3.4%

Shares of Eli Lilly and Company stock opened at $1,062.67 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.00 trillion, a price-to-earnings ratio of 51.99, a PEG ratio of 1.14 and a beta of 0.37. The company’s 50-day moving average price is $943.82 and its 200-day moving average price is $822.76.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the business earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Scotiabank started coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective on the stock. Bank of America decreased their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday. Finally, BMO Capital Markets set a $1,200.00 target price on shares of Eli Lilly and Company in a research report on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,128.55.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.